Publisher
Springer Science and Business Media LLC
Reference79 articles.
1. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E. Patients’ age and BCR::ABL1 frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112:918–9. https://doi.org/10.1182/blood-2008-04-149286.
2. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489–96. https://doi.org/10.1182/blood-2009-01-199380.
3. Shi T, Xie M, Chen L, Yuan W, Wang Y, Huang X, et al. Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era. Exp Hematol Oncol. 2022;11:13. https://doi.org/10.1186/s40164-022-00265-2.
4. Bergfelt Lennmyr E, Engvall M, Barbany G, Fogelstrand L, Rhodin H, Hallböök H. Cytogenetic aberrations in adult acute lymphoblastic leukemia—a population-based study. EJHaem. 2021;2:813–7. https://doi.org/10.1002/jha2.300.
5. Cimino G, Pane F, Elia L, Finolezzi E, Fazi P, Annino L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica. 2006;91:377–80.